These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 23289795

  • 1. Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.
    Wolnik B, Hak L.
    Expert Opin Drug Saf; 2013 Mar; 12(2):137-44. PubMed ID: 23289795
    [Abstract] [Full Text] [Related]

  • 2. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 3. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
    Balaji V, Balaji MS, Alexander C, Srinivasan A, Suganthi SR, Thiyagarajah A, Seshiah V.
    Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
    [Abstract] [Full Text] [Related]

  • 4. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [Abstract] [Full Text] [Related]

  • 8. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S, Liu X, Ming J, Ji Q.
    Trials; 2016 Mar 24; 17():160. PubMed ID: 27009108
    [Abstract] [Full Text] [Related]

  • 9. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G.
    J Diabetes; 2016 Sep 24; 8(5):720-8. PubMed ID: 26612062
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr 24; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [Abstract] [Full Text] [Related]

  • 11. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J, IMPROVE Study Expert Panel.
    Curr Med Res Opin; 2013 Jun 24; 29(6):601-9. PubMed ID: 23488447
    [Abstract] [Full Text] [Related]

  • 12. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
    Chen SF, Li H.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug 24; 32(8):827-9. PubMed ID: 22093477
    [Abstract] [Full Text] [Related]

  • 13. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr 24; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [Abstract] [Full Text] [Related]

  • 14. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.
    Diabetes Res Clin Pract; 2013 Apr 24; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [Abstract] [Full Text] [Related]

  • 15. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S, Hyllested-Winge J, Gall MA, Kaneko S, Hirao K.
    J Diabetes; 2017 Mar 24; 9(3):243-247. PubMed ID: 27059529
    [Abstract] [Full Text] [Related]

  • 16. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
    Chen L, Xing X, Lei M, Liu J, Shi Y, Li P, Qin G, Li C, Li Y, Wang Q, Gao T, Hu L, Wang Y, Yang W.
    Chin Med J (Engl); 2014 Mar 24; 127(2):208-12. PubMed ID: 24438605
    [Abstract] [Full Text] [Related]

  • 17. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E.
    Diabetes Metab; 2015 Jun 24; 41(3):223-30. PubMed ID: 25483023
    [Abstract] [Full Text] [Related]

  • 18. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
    El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.
    Diabetes Res Clin Pract; 2012 Dec 24; 98(3):408-13. PubMed ID: 23217267
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
    Trippe BS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Oyer DS.
    Curr Med Res Opin; 2012 Jul 24; 28(7):1203-11. PubMed ID: 22509859
    [Abstract] [Full Text] [Related]

  • 20. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 24; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.